<DOC>
	<DOCNO>NCT01052116</DOCNO>
	<brief_summary>The trial design study effect soy supplement asthma control .</brief_summary>
	<brief_title>The Study Soy Isoflavones Asthma</brief_title>
	<detailed_description>Asthma common disease major impact morbidity health care cost . Although prevalence severity asthma increase last several decade , specific cause remain unknown . One possible mechanism change diet . Yet , epidemiological interventional study design identify key nutrient antioxidant vitamin may responsible increase disease severity produce inconsistent result . A recent pilot study show soy isoflavone supplement reduces exhale nitric oxide ( FeNO ) ex vivo LTC4 synthesis patient inadequately control asthma . This clinical trial design test novel hypothesis dietary supplementation soy isoflavones effective treatment patient poorly control asthma . The study include 380 patient low dietary soy intake , 12 year age old , take either inhaled corticosteroid leukotriene modifier inadequately control asthma . Participants randomly assign treatment either soy isoflavone supplement ( contain genistein , daidzein glycitein ; 100 mg daily glycoside form ) placebo six month . The result trial increase understanding role diet asthma ; could identify novel , safe relatively inexpensive treatment patient asthma ; potentially substantial impact public health United States .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Age 12 old Physician diagnose asthma FEV1 equal great 50 % predict prebronchodilator At least 12 % increase FEV1 153 minute inhale 24 puff albuterol positive methacholine challenge ( 20 % fall FEV1 le 8 mg/mL ) . Either available previous 2 year Currently prescribe daily controller asthma medication Poor asthma control ( least one follow ) A score 1.5 great Juniper Asthma Control Questionnaire Use betaagonist asthma symptoms two time per week Nocturnal awakening asthma symptom per week Two episode asthma symptom past 12 month require least one following : emergency department visit , unscheduled physician visit , prednisone course , hospitalization Smoking status Nonsmoker 6 month longer Less 10 packyears smoke history Pulmonary function FEV1 le 50 % predict prebronchodilator Other major chronic illness Conditions judgment study physician would interfere participation study , e.g. , nonskin cancer , endocrine disease , coronary artery disease , severe hypertension , immunodeficiency state History thyroid disease , breast cancer , ovarian , endometrial cancer History physician diagnosis chronic bronchitis , emphysema , COPD Medication use Current consumption soy isoflavone supplement Oral corticosteroid use within past 6 week Use tamoxifen Use investigational treatment previous 30 day `` Drug '' allergy Known adverse reaction genistein , phytoestrogens , soy product Females childbearing potential Pregnant lactating . Participants must agree use effective contraception trial . Nonadherence Inability unwillingness provide consent , case child , inability unwillingness child provide assent Inability swallow study medication Inability perform baseline measurement Completion less 10 last 14 day diary entry screen period Inability contact telephone Intention move area within 6 month Other Recent asthma exacerbation ( within 6 week ) Recent upper respiratory infection ( within 2 week ) Body weight less 77 pound ( 35 kg ) Intake soy soyenriched food 1 time week Change diet past month expect change diet study</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Soy</keyword>
	<keyword>Supplement</keyword>
	<keyword>ACRC</keyword>
	<keyword>SOYA</keyword>
</DOC>